ARS Pharmaceuticals, Inc.

SPRY

$1.01B

Small Cap

NASDAQBiotechnology🇺🇸North America162 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jun 15, 2026

25w

Drug Pipeline

Drug Name	Phase	Indication	Designations
ARS-1	Phase 2	Asthma	-
Placebo	Phase 2	Urticaria	-
0.5 mg epinephrine	Phase 2	Urticaria Chronic	-

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

0.5 mg epinephrine Phase 2 Results Expected

June 2026~0.5 mg epinephrine

Primary completion for 0.5 mg epinephrine trial (NCT06927999) in Urticaria Chronic

Source

Phase 2

Placebo Phase 2 Results Expected

June 2026~Placebo

Primary completion for Placebo trial (NCT06927999) in Urticaria Chronic

Source

Regulatory Approvals

SPRY News

ARS Pharmaceuticals, Inc.

SPRY

$1.01B

Small Cap

NASDAQBiotechnology🇺🇸North America162 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jun 15, 2026

25w

Drug Pipeline

Drug Name	Phase	Indication	Designations
ARS-1	Phase 2	Asthma	-
Placebo	Phase 2	Urticaria	-
0.5 mg epinephrine	Phase 2	Urticaria Chronic	-

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

0.5 mg epinephrine Phase 2 Results Expected

June 2026~0.5 mg epinephrine

Primary completion for 0.5 mg epinephrine trial (NCT06927999) in Urticaria Chronic

Source

Phase 2

Placebo Phase 2 Results Expected

June 2026~Placebo

Primary completion for Placebo trial (NCT06927999) in Urticaria Chronic

Source

Regulatory Approvals

SPRY News